Vyvanse generics approved
The FDA approved the first generics of Vyvanse, with roughly 15 manufacturers cleared for both capsule and chewable forms. The approvals introduce multiple suppliers into the market and likely complicate product traceability for adverse‑event reports. (managedhealthcareexecutive.com)
Vyvanse now has U.S. generics, ending Takeda’s run as the only seller after the drug’s exclusivity expired in late August 2023. (reuters.com) The drug’s generic name is lisdexamfetamine dimesylate, a stimulant used to treat attention deficit hyperactivity disorder in adults and children age 6 and older, and moderate to severe binge-eating disorder in adults. Brand Vyvanse comes as capsules and chewable tablets. (dailymed.nlm.nih.gov, accessdata.fda.gov) Reuters reported on August 31, 2023, that the Food and Drug Administration had approved generic versions from 11 drugmakers, and industry trade coverage at the time counted about 14 to 15 approved manufacturers across the capsule and chewable products. Hikma said the same day that it had received approval and launched 20 milligram through 70 milligram capsules in the United States. (reuters.com, hikma.com, additudemag.com) Generic approval does not mean one factory suddenly replaces one brand. The Food and Drug Administration’s Orange Book lists approved products and therapeutic equivalents, while the National Drug Code directory tracks the specific labeled products and package identifiers that move through pharmacies. (fda.gov, fda.gov) That matters for patients who were already dealing with supply problems. The American Society of Health-System Pharmacists still listed lisdexamfetamine dimesylate capsules in shortage on April 2, 2026, with some companies available, some limited, and others constrained by active-ingredient issues. (ashp.org) The approvals also changed the economics around one of Takeda’s biggest attention deficit hyperactivity disorder products. Takeda told investors in its 2023 annual report that it expected “significant headwinds” from the loss of high-margin Vyvanse to generic competition. (sec.gov) For pharmacists and prescribers, the practical shift is substitution and sourcing. A patient may receive the same active ingredient from different labelers over time, depending on stock, contracts, and shortages, even when the prescription itself does not change. (fda.gov, ashp.org) For patients, the label on the bottle now matters more than it did when one brand dominated the market. The National Drug Code, manufacturer name, strength, and dosage form can help a pharmacy, doctor, or Food and Drug Administration safety report pinpoint which product was dispensed if a shortage, switch, or side-effect question comes up later. (fda.gov, dailymed.nlm.nih.gov)
